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The physiological roles of the betaine/GABA transporter (BGT1; slc6a12) are still being
debated. BGT1 is a member of the solute carrier family 6 (the neurotransmitter, sodium
symporter transporter family) and mediates cellular uptake of betaine and GABA in a
sodium- and chloride-dependent process. Most of the studies of BGT1 concern its function
and regulation in the kidney medulla where its role is best understood. The conditions here
are hostile due to hyperosmolarity and significant concentrations of NH4Cl and urea. To
withstand the hyperosmolarity, cells trigger osmotic adaptation, involving concentration of
a transcriptional factor TonEBP/NFAT5 in the nucleus, and accumulate betaine and other
osmolytes. Data from renal cells in culture, primarily MDCK, revealed that transcriptional
regulation of BGT1 by TonEBP/NFAT5 is relatively slow. To allow more acute control of
the abundance of BGT1 protein in the plasma membrane, there is also post-translation
regulation of BGT1 protein trafficking which is dependent on intracellular calcium and ATP.
Further, betaine may be important in liver metabolism as a methyl donor. In fact, in the
mouse the liver is the organ with the highest content of BGT1. Hepatocytes express
high levels of both BGT1 and the only enzyme that can metabolize betaine, namely
betaine:homocysteine –S-methyltransferase (BHMT1). The BHMT1 enzyme removes a
methyl group from betaine and transfers it to homocysteine, a potential risk factor for
cardiovascular disease. Finally, BGT1 has been proposed to play a role in controlling brain
excitability and thereby represents a target for anticonvulsive drug development. The latter
hypothesis is controversial due to very low expression levels of BGT1 relative to other
GABA transporters in brain, and also the primary location of BGT1 at the surface of the
brain in the leptomeninges. These issues are discussed in detail.
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BACKGROUND
Osmotic stress occurs in several tissues and has been studied most
extensively in cells in the inner medulla of the kidney. In humans
these cells are normally exposed to low oxygen tension, ammo-
nia, and very high levels (600 mOsm) of both NaCl and urea
when urine is maximally concentrated. Numerous perturbations
can result from the hypertonic effect of high NaCl and the dena-
turing effect of high urea. These include production of reactive
oxygen species, cytoskeletal rearrangements, inhibition of DNA
replication, transcription, and translation, and damage to DNA
and mitochondria (Burg et al., 2007; Cheung and Ko, 2013).
Abbreviations: BGT1, sodium/chloride-dependent betaine-GABA trans-
porter (slc6a12); BHMT1, betaine:homocysteine –S-methyltransferase;
EF1502, N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-4-(methylamino-4,5,6,7-
tetrahydrobenzo[d]isoxazol-3-ol; GABA, γ-aminobutyric acid; GAT, GABA
transporter; IBD, inflammatory bowel disease; MDCK, Madin-Darby canine kid-
ney; MTHFR, methylenetetrahydrofolate reductase; OCTN2, carnitine transporter
(Slc22a5); SMIT1, sodium-dependent myo-inositol cotransporter-1 (slc5a3);
SNAT1, Slc38a1 (previously referred to as ATA1, GlnT, SA2, SAT1, or mouse
NAT2); SNAT2, Slc38a2 (previously referred to as SAT2, ATA2, KIAA1382, SA1);
SNAT4, Slc38a4 (previously referred to as PAAT, NAT3, ATA3, SAT3), amino acid
system A transporters; TAUT, sodium/chloride-dependent taurine transporter
(slc6a6); TonEBP, tonicity-responsive enhancer binding protein, also known as
NFAT5, nuclear factor of activated T cells-5.
Adaptation is essential for survival and the adaptations by
medullary cells are extensive (Lee et al., 2011). Many are driven
by the transcription factor TonEBP/NFAT5 (Burg et al., 1997;
Cheung and Ko, 2013). Compared to cells grown in culture,
renal medullary cells appear to be more tolerant in vivo in part
because conditions changemore slowly and because adaptation to
osmotic stress may confer tolerance to other stresses (Santos et al.,
2003). However, cell death occurs by apoptosis when the adap-
tations fail (Go et al., 2004; Lam et al., 2004; Lopez-Rodriguez
et al., 2004; Moeckel, 2013). The adaptive mechanisms include
increased expression of heat shock proteins and accumulation of
organic osmolytes (Neuhofer and Beck, 2005; Kwon et al., 2009).
These osmolytes are termed “compatible” because, in contrast to
electrolytes, they do not perturb the function of macromolecules
when present at high intracellular concentrations (Yancey et al.,
1982).
Betaine, which is found in many foods including spinach and
wheat, is also one of the important osmolytes in the kidney
medulla. Betaine transport activity was discovered in Madin-
Darby canine kidney (MDCK) cells (Nakanishi et al., 1990), and
screening of a MDCK cell cDNA library for expression of betaine
transport activity in Xenopus oocytes resulted in isolation of a
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betaine transporter cDNA (Yamauchi et al., 1992). The nucleotide
sequence turned out to be closely related to those of brain trans-
porters for γ-amino-n-butyric acid (GABA) and noradrenalin
(Gadea and López-Colome, 2001; Eulenburg and Gomeza, 2010).
Because the novel transporter was able to transport not only
GABA, but also betaine, it was named the betaine-GABA trans-
porter (BGT1; slc6a12). In parallel, two other research groups
independently cloned BGT1 homologs from mouse (López-
Corcuera et al., 1992) and human brain (Borden et al., 1995a)
based on homology to GABA transporter 1 (GAT1; slc6a1)
(Guastella et al., 1990). Soon thereafter, BGT1 was also cloned
from rat liver (Burnham et al., 1996) and from human kidney
(Rasola et al., 1995). Most of the studies of BGT1 concern its
function and regulation in the kidney medulla where its role
in osmolyte transport has been well-defined. Its presence in the
brain and liver is well-documented, but its role in these tissues
has not been studied extensively.
It is important to note that the mouse isoform was origi-
nally calledmouse GAT2 ormGAT2 (López-Corcuera et al., 1992)
and that BGT1 therefore should not be confused with rat/human
GAT2 (slc6a13) which does not transport betaine. BGT1 expres-
sion may vary among species. In the dog, BGT1 mRNA was
primarily detected in the kidney while the levels in the brain
and liver were considerably lower (Roberts, 1974; Yamauchi et al.,
1992). The highest BGT1 mRNA levels in the mouse were found
in the liver (López-Corcuera et al., 1992) while the highest lev-
els in man were in the kidney followed by the liver (Rasola et al.,
1995).
BGT1 AND BETAINE IN BRAIN
Because GABA is the major inhibitory neurotransmitter in the
adult mammalian brain (Roberts, 1974; Krnjevic, 2004) and its
action is terminated by cellular uptake catalyzed by the GABA
transporters, these transporters are highly interesting as tar-
gets for the development of anticonvulsant and antiepileptic
drugs (Gadea and López-Colome, 2001; Eulenburg and Gomeza,
2010). The mammalian genome contains four genes encod-
ing GABA transporters, namely GAT1 (slc6a1), GAT2 (slc6a13),
GAT3 (slc6a11), and BGT1 (slc6a12). Tiagabine (marketed under
the name Gabitril®) is the only clinically approved GABA trans-
porter inhibitor, and is used for treatment of mesial temporal lobe
epilepsy. The use of tiagabine, however, is limited by its short
half-life and side effects (dizziness, fatigue, confusion, tremor,
ataxia, and nervousness). Side effects are not surprising consid-
ering that tiagabine is a selective GAT1 inhibitor (Nielsen et al.,
1991; Borden, 1996; Krogsgaard-Larsen et al., 2000) and that
GAT1-knockout mice display similar signs (Chiu et al., 2005). On
this background it makes sense to determine if the other GABA
transporter subtypes (GAT2, GAT3, and BGT1) represent bet-
ter drug targets. Consequently, medicinal chemists developed a
number GABA uptake inhibitors (Krogsgaard-Larsen et al., 2000;
Soudijn and vanWijngaarden, 2000; Andersen et al., 2001) as well
as novel assays for compound screening (Sindelar and Wanner,
2012; Polley et al., 2013).
On this background, a novel GABA uptake inhibitor N-[4,4-
bis(3-methyl-2-thienyl)-3-butenyl]-4-(methylamino-4,5,6,7-tet
rahydrobenzo[d]isoxazol-3-ol (EF1502), which inhibits both
GAT1 and BGT1, but not GAT2 and GAT3, was produced
(Clausen et al., 2006). This compound was subsequently reported
to be synergistic to the GAT1 inhibitor tiagabine in protection
against seizures. These observations were interpreted as evidence
for a functional role for BGT1 in seizure control (White et al.,
2005; Clausen et al., 2006), and investigations of brain BGT1
suddenly became a hot topic.
However, a role of BGT1 in the brain was surprising con-
sidering the low expression levels (López-Corcuera et al., 1992;
Burnham et al., 1996) and lower affinity for GABA than those
of the other GABA transporters. The reported Km values for
the mouse isoforms are 0.8, 8, 18, and 80μM, respectively, for
GAT3, GAT1, GAT2, and BGT1 (López-Corcuera et al., 1992; Liu
et al., 1993; Matskevitch et al., 1999). This was clear to Borden
(Borden, 1996) and he wrote that BGT1: “is unlikely to play a
major role in terminating the action of GABA at a synapse” due
to low levels. But then, possibly to keep all options open, added
that: “It may, however, serve to sequester GABA that has diffused
away from synaptic regions, thereby assuring the fidelity of trans-
mission.” [This argument seemed plausible based on the limited
understanding of neurotransmitter diffusion at the time, but see
below]. In agreement, Smith et al. (2008) reported that they had
used two GABA transport inhibitors to modulate inhibitory tone
via inhibition of GAT1 (with tiagabine) or BGT1 (with EF1502)
and found differential effects in an in vitro model of sponta-
neous interictal-like bursting. This paper also cites a paper by Ahn
et al. (1996) for support to the notion that BGT1 is in dendrites.
However, in this study BGT1 cDNA was microinjected into cul-
tured hippocampal neurons. When that was done, it was found
that BGT1 was primarily targeted to the dendrites, but (obvi-
ously) that does not tell if cells in the brain actually express the
protein in the first place.
Researchers tried to localize BGT1 in the brain and in cell
cultures (Borden, 1996), but there was a great deal of uncer-
tainty. BGT1mRNAwas reported in cultured astrocytes and in an
astrocytoma cell line, but not in cultured neurons (Borden et al.,
1995b; Bitoun and Tappaz, 2000; Ruiz-Tachiquin et al., 2002).
BGT1 protein was reported in brain endothelium (Takanaga et al.,
2001), in astrocyte and astrocytoma cultures, under hyperosmotic
conditions in particular (Ruiz-Tachiquin et al., 2002; Olsen et al.,
2005), in pyramidal neurons (but not astrocytes) in untreated
rats (Zhu and Ong, 2004a), in astrocytes in kainate injected rats
(Zhu and Ong, 2004a) and in Macaca fascicularis monkeys (Zhu
and Ong, 2004b). The latter investigators observed BGT1 label in
dendritic spines, not at GABAergic synapses, but at glutamatergic
synapses and referred to this as BGT1 being localized in “an extra-
perisynaptic region, away from the post-synaptic density” (Zhu
and Ong, 2004b). This was interpreted as evidence in support
of Borden’s suggestion (see above). However, these immunocy-
tochemical data could not be validated because knockout animals
were unavailable at the time to serve as negative controls. For the
importance of this see our previous studies (Holmseth et al., 2006,
2012). Further, these data were mostly based on the same anti-
body from Chemicon (Temecula, CA, USA) to the 15 C-terminal
amino acids of rat BGT1. Unfortunately, we now know that
this sequence differs between species raising concerns about the
specificity:
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PAKEGLIAGEKETHL [Macaca fascicularis]
PVKQELIAWEKETHL [Rattus norvegicus]
PAKQELIAWEKETHL [Mus musculus]
It is still possible that the antibodies recognize the monkey ver-
sion, but according to our experience with peptide antibodies this
is not very likely (Danbolt et al., 1998; Holmseth et al., 2005, 2012)
and it was not tested (Zhu and Ong, 2004a,b) whether the anti-
body recognized after aldehyde fixation (Holmseth et al., 2012) as
a lysine residue (yellow) can be affected by fixation. Further, there
is poor correlation between the brain regions reported to have
the highest immunoreactivity (Zhu and Ong, 2004a,b) and those
with the highest BGT1 mRNA levels (Zhou et al., 2012a). Thus,
these immunocytochemistry data can be disregarded. Having said
that, our data (Zhou et al., 2012a) do not exclude the possibil-
ity that the labeling observed in astrocytes after kainate injection
could be due to BGT1 (Zhu and Ong, 2004a,b). But if BGT1 is
present in astrocytes, then it will be expressed in between a much
higher number of GAT3 transporters (Conti et al., 2004) which
have (as explained above) also higher affinity. This would in itself
invalidate the notion about “an extra-perisynaptic region away
from the post-synaptic density.”
This led to a great deal of uncertainty and, at the same time, the
questions were important. If EF1502, despite low BGT1 expres-
sion levels, did mediate its effects via BGT1 then there might be
something new and important to learn. Alternatively, if EF1502
did not mediate its effects via BGT1 then it might be worthwhile
to identify the other target. To resolve this issue, BGT1 knock-
out mice were developed (Lehre et al., 2011) and subjected to
seizure threshold testing. To exclude differences caused by other
factors, such as age, gender, and environment, BGT1 wild type
and knockout littermates were used. The mice were subjected
to a series of seizure threshold tests including pentylentetrazol
(PTZ) seizure threshold test, minimal clonic seizure threshold
test, the 6Hz seizure threshold tests, and minimal tonic extension
threshold test (Lehre et al., 2011). Unexpectedly, no differences in
seizure thresholds were noted between BGT1 knockout and wild
typemice (Lehre et al., 2011). EF1502 is an anticonvulsant in both
the BGT1 wild type and knockout mice presumably because of
its dual function of also inhibiting GAT1. In fact, in our hands,
EF1502 was somewhat more potent in the BGT1-deficient mice
(Lehre et al., 2011). Thus, these experiments did not provide
any indication whatsoever that BGT1 plays a role in controlling
seizure thresholds.
Lack of differences in seizure thresholds needed an expla-
nation, and the BGT1 expression levels and distributions were
determined using the knockout mice as negative controls to ver-
ify labeling specificity. Although it was already known that the
brain BGT1 levels were low, it was unexpected to find that BGT1
is expressed at levels 2–3 orders of magnitude lower than those of
GAT1 inmice (Lehre et al., 2011) and thatmost of BGT1 is located
at the surface of the brain, in the leptomeninges, rather than in
brain tissue proper (Figure 1), also see Figure 9 in Zhou et al.
(2012a). This result is further supported by an in situ hybrization
study (Evans et al., 1996) and mass spectroscopy data (Nielsen
et al., 2005; Lu et al., 2009; Walther and Mann, 2011). As GAT2 is
also expressed at low levels in mouse brain tissue proper (Zhou
FIGURE 1 | BGT1 is expressed in the leptomeninges. The sections from
wildtype and knockout were labeled with anti-BGT1 antibody (red; Ab#590;
1μg/ml), and with anti-CD31 antibodies (green; 0.5μg/ml; endothelial
marker). The images from the sections from knockout mice are not shown
here. Scale bars = 20μm. Immunochemistry was performed using the
same materials and procedures described in detail by Zhou et al. (2012a).
et al., 2012b), this implies that GAT1 and GAT3 are the most
important ones in the rodent central nervous system (Conti et al.,
2004; Zhou and Danbolt, 2013).
In quiescent tissue the ambient GABA levels around synapses
are relatively low (Westergren et al., 1994), possibly as low as
suggested for glutamate (Herman and Jahr, 2007), and thereby
well-below the Km of GAT3. The mouse isoforms of GAT1 and
GAT3 have, respectively, about 10 and 100 times higher affinity
for GABA than BGT1. Thus, GABA is assumed to be effectively
removed to a level where BGT1 becomes inefficient. Because
GABA levels can rise to high levels during periods of intense
synaptic activity (Semyanov et al., 2004; Olah et al., 2009), it is
conceivable that there are situations when BGT1 may be acti-
vated. However, this is highly unlikely to have any effect on GABA
uptake because our comparison indicates that the BGT1 levels
are approximately 100–1000 times lower than those of GAT1,
and available data from the literature (Mager et al., 1993; Sacher
et al., 2002; Karakossian et al., 2005; Gonzales et al., 2007) do
not suggest that BGT1 is any faster than the other GABA trans-
porters. Thus, even when GABA levels are high, the BGT1 can
at most be responsible for 0.1–1.0% of the transport. The con-
tribution will be far less at lower GABA levels. Furthermore,
neurotransmitters diffuse rapidly out of the synaptic cleft on a
low microsecond timescale until they bind to transporters and
are removed (Clements, 1996; Danbolt, 2001; Lehre and Rusakov,
2002; Rusakov et al., 2005). Thus, unless there are more trans-
porters in the immediate vicinity of synapses than released GABA
molecules, then GABA molecules will pass by all occupied trans-
porters diffusing multiple synapse diameters away before the
occupied transporters are ready for a new transport cycle. This
rules out a role for BGT1 in controlling GABA levels in mice,
www.frontiersin.org April 2014 | Volume 5 | Article 159 | 3
Kempson et al. BGT1 transporter and betaine
and explains why there were no significant differences between
wildtype and BGT1-deficient mice in seizure thresholds. Thus,
if BGT1 plays any role in brain tissue proper this cannot be due
to its ability to transport GABA. Its role must be either to trans-
port something else or a novel function requiring very few BGT1
molecules.
Recently a novel role of BGT1 and betaine has been proposed
(Peden et al., 2013) based on studies in C. elegans. The betaine
transporter in this nematode species is termed SNF-3 and is a
BGT1 ortholog that is Na+ and Cl− dependent. However, SNF-3
differs from mammalian BGT1 in that it transports only betaine
not GABA. The SNF-3 functions primarily in the epidermis where
its role is to remove extracellular betaine which is toxic to nema-
todes. The toxicity is probably due to constitutive activation of
the betaine receptor by excess extracellular betaine. The recep-
tor is a betaine gated cation channel (ACR-23) which is localized
in body muscle and neurons (Rufener et al., 2013). Inactivation
of SNF-3 was associated with hypercontraction and paralysis of
the worms due to excess betaine (Peden et al., 2013). This study
suggests that betaine has a signaling role and some earlier stud-
ies in mice lend support to this notion. For example, betaine was
reported to have anti-epileptic properties (Freed et al., 1979), and
can partly rescue the brain atrophy in MTHFR deficient mice
(Schwahn et al., 2004). More recently it was reported that betaine
can elevate growth hormone levels and activate IGF-1 signaling
pathways in pig, mouse and rat tissues (Lee et al., 2006; Huang
et al., 2007; Senesi et al., 2013).
The vertebrate brain, however, contains low amounts of
betaine (Gullans and Verbalis, 1993; Slow et al., 2009) (Table 1)
which is probably derived from exogenous betaine (Schwahn
et al., 2004) via non-specific organic solute transporters across the
blood brain barrier. Most of the dietary betaine is utilized by liver
and kidney (Pummer et al., 2000; Kettunen et al., 2001; Kim et al.,
2003), see detailed discussion below. Further, the need for high
doses (intraperitoneal) to attenuate PTZ-induced seizures may
be due to poor transport across the blood brain barrier because
betaine was more potent when injected directly into the ventri-
cles (Ghoz and Freed, 1985). However, as explained above BGT1
protein is, at least in mice, not significantly present in either neu-
rons or glia (Zhou et al., 2012a) implying that the betaine removal
capacity around synapses is extremely low. This is also consis-
tent with the finding that wildtype and BGT1-deficient mice have
similar seizure thresholds (Lehre et al., 2011). However, consid-
ering that BGT1 is expressed in the leptomeninges (Zhou et al.,
2012a), it is legitimate to ask if BGT1 can contribute to betaine
removal via the newly discovered glymphatic pathway, which is a
key contributor to the clearance of interstitial solutes (Iliff et al.,
2012). Further studies are needed before any firm conclusion can
be made concerning a signaling role of betaine and BGT1 in the
mammalian brain.
Could BGT1 and betaine play a role in modulating cell volume
in the brain? Considering the abundance of the other osmolyte
transporters SMIT and TAUT and the relative levels of osmolytes
in the brain (Table 1) (Heilig et al., 1989; Zhou et al., 2012a) a
role of BGT1 in maintaining cellular volume in brain is probably
insignificant. This argument is further strengthened by the low
level of brain betaine (Slow et al., 2009), the lack of change of
Table 1 | Summary of osmolyte concentrations in mouse tissues.
Content Brain Kidney Liver References
(µmol/g) (µmol/g) (µmol/g)
Betaine 0.02–0.1 1–5 1–10 Schwahn et al., 2004; Clow
et al., 2008; Teng et al., 2011
Taurine 5–10 8–20 5–15 Brosnan and Brosnan, 2006;
Warskulat et al., 2006; Zhou
et al., 2012b; Roman et al.,
2013; Bjørnsen et al., 2014
myo-inositol 5–7 6–7 0.3–0.6 Chau et al., 2005; Bjørnsen
et al., 2014
brain betaine content with either salt loading or water deprivation
(Heilig et al., 1989; Lien et al., 1990; Zhou et al., 2012a), and the
lack of a significant increase of BGT1mRNA in brain during acute
and chronic salt loading (Kaneko et al., 1997).
In summary the roles of BGT1 and betaine in brain, and possi-
ble regulation by TonEBP/NFAT5, have not been determined. As
discussed above, BGT1 is unlikely to be involved in GABA and
betaine transport in brain tissue proper, at least in normal mice
brains. Thus, the hypothesis reviewed inMadsen et al. (2010) that
inhibition of BGT1 can delay removal of GABA from extrasynap-
tic GABA receptors due to its “peri-extrasynaptic localization” is
refuted. On the other hand, the fairly high levels of BGT1 in the
leptomeninges suggest that BGT1 is present in sufficient concen-
trations to perform a physiologically relevant function although
the nature of this function remains to be discovered.
BGT1 AND BETAINE IN KIDNEY
It is now well-established that the primary role of betaine in the
kidney is osmoprotection. The always high but changing extracel-
lular osmolarity in the kidney medulla plays an essential role in
urine concentration. To balance the high osmolarity and preserve
cell volume without interfering with cell function, one well-
characterized mechanism is to accumulate compatible osmolytes
(Miyakawa et al., 1999a). Betaine, sorbitol, myo-inositol, taurine,
and glycerolphosphorylcholine are the predominant osmolytes in
the mammalian kidney and MDCK cells (Bagnasco et al., 1986),
and the function of these osmolytes had been discussed in detail
elsewhere (Burg and Ferraris, 2008). The accumulation of betaine
is primarily due to the presence of BGT1 and is influenced by
tonicity (Nakanishi et al., 1990; Yamauchi et al., 1992; Handler
and Kwon, 1996). MDCK cells have been used extensively as a
model for studying the potential functions of BGT1 in the kid-
ney, in part because they were derived from the distal nephron
(Ojakian et al., 1987) and because a wealth of information on
epithelial cell behavior is available from studies in this cell line
(Dukes et al., 2011). Under the isotonic condition BGT1 is mainly
in the cytoplasm in MDCK cells (Basham et al., 2001; Kempson
et al., 2003) and the betaine transport capacity of the cells is low
(Nakanishi et al., 1990; Kempson, 1998). Hypertonicity increases
betaine transport, primarily in the basolateral plasma membrane,
by activating transcription of the BGT1 gene. This increases abun-
dance of BGT1 mRNA more than 10-fold and increases the
transport capacity 5–10 fold (Yamauchi et al., 1991; Uchida et al.,
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1993; Kempson, 1998). Activation of transcription is achieved
by tonicity-responsive enhancer sequences (TonE1 and TonE2)
that are present in the promoter region of the BGT1 gene and
specifically bind the TonE binding proteins (TonEBP/NFAT5’s)
(Takenaka et al., 1994; Miyakawa et al., 1998, 1999b). Up- and
down-regulation of BGT1 mRNA transcription in response to
changes in medullary tonicity has been confirmed also in vivo
(Kaneko et al., 1997). In MDCK cells the transcriptional regu-
lation of BGT1 by TonEBP/NFAT5 and subsequent upregulation
of betaine transport is relatively slow, requiring up to 20 h for
completion (Yamauchi et al., 1991; Kempson, 1998). Using the
same cell line we have identified more acute control of plasma
membrane abundance of BGT1 (Kempson et al., 2003, 2005;
Kempson and Montrose, 2004; Lammers et al., 2005). In addi-
tion we have reported changes in post-translational regulation of
BGT1 protein trafficking within 30–60min in response to changes
in concentrations of extracellular calcium (Kempson et al., 2006;
Parikh et al., 2013), ATP and adenosine (Kempson et al., 2008).
The common mechanism is endocytic removal of pre-existing
BGT1 protein from the basolateral plasma membrane which
would be useful when cellular accumulation of betaine was no
longer required. In contrast, nitric oxide which is produced in
the renal medulla is response to hypertonic extracellular NaCl
(Kempson et al., 2007) upregulates BGT1 transport in MDCK
cells. The mechanism is not understood but the result is increased
delivery of BGT1 protein to the plasma membrane, as detected by
total internal reflection fluorescence (TIRF) microscopy (Kempson
et al., 2011). The response to nitric oxide may be complex since an
earlier study reported that nitric oxide directly inhibits the tran-
scriptional activity of TonEBP/NFAT5 (Neuhofer et al., 2009). It is
notable that BGT1, unlike the other GABA transporter subtypes,
is acutely regulated by extracellular pH (Matskevitch et al., 2000;
Grossman and Nelson, 2002, 2003). In summary, these acute
acting factors provide a system of checks and balances that fine-
tune the capacity for betaine accumulation during fluctuations in
hypertonicity in the renal medulla.
At the molecular level, the transport mechanism and specific
sites that bind and couple betaine transport to the movement
of Na+ and Cl− ions are not understood. This is in marked
contrast to the detailed information on bacterial Na+-coupled
betaine transporters such as BetP (Ott et al., 2008; Perez et al.,
2012). The basolateral targeting information for BGT1 lies within
a short segment of amino acids (565–572) that is rich in basic
residues and located within the cytoplasmic C-terminus (Perego
et al., 1997). An additional requirement for accurate targeting
during hypertonic upregulation appears to be phosphorylation
at T40 located in a cytoplasmic loop near the N-terminus. This
is based on our observation that when T40, a potential phospho-
rylation site, was mutated to alanine to prevent phosphorylation
the T40A mutant form of BGT1 was trapped intracellularly in the
trans-Golgi network. In contrast, when T40 was mutated to either
glutamate or aspartate to mimic phosphorylation at T40, both the
T40E and T40D forms of BGT1 were found to traffic normally to
the plasma membrane during hypertonic stress (Anderson et al.,
2010; Day et al., 2012) (Kempson, unpublished data). This sug-
gests that T40 near the N terminus may be part of a hot spot for
normal trafficking or insertion of BGT1 in the plasmamembrane.
Following delivery and insertion, the retention of BGT1 in the
plasmamembrane depends on the association between BGT1 and
the LIN7 PDZ membrane protein which involves a PDZ target
sequence in the last 5 residues at the C terminus of the transporter.
This association is regulated by protein kinase C and T612 is an
essential target. Phosphorylation of T612 disrupts the association
and leads to internalization of BGT1 (Massari et al., 2005). Apart
from these few studies, little is known about structure-function
relationships in renal BGT1.
Even though BGT1 has been suggested for more than two
decades to play an important role in osmolyte accumulation and
survival of the renal medullary cells, the localization of BGT1
protein in vivo was not reported until recently. Zhou and col-
leagues detected BGT1 protein at low levels in the renal outer
medulla, and at very high concentration in the renal papilla
(Figures 2A,C). Also see Figure 6 in Zhou et al. (2012a) which
is in agreement with the in situ hybridization data (Miyai et al.,
1996). BGT1 protein was in the basolateral membrane of cells in
the collecting ducts, and in the cytoplasm of cells in the thick
ascending limb of Henle’s loop. Also see Figure 7 in Zhou et al.
(2012a). It should be noted that in the collecting ducts in the outer
medulla BGT1 was present in a few sparse cells, presumably inter-
stitial cells (Figure 2B). Also see Figure 7B in Zhou et al. (2012a).
Mice lacking BGT1 were viable and, unexpectedly, they concen-
trated urine and showed no ill effects after 72 h of salt drinking
(Lehre et al., 2011; Zhou et al., 2012a). There was no detailed
FIGURE 2 | BGT1 localization in the kidney. The kidney sections from
wildtype and knockout were labeled with anti-BGT1 antibody (red; Ab#590;
1μg/ml), and with fluorescein-conjugated D. biflorus agglutinin (green;
1:300; marker for collecting ducts). (A,B) are from the outer strip of outer
medulla, and (C,D) are from the tip of the renal papilla. The images from
the sections from knockout mice are not shown here. Scale bars for (A,C)
= 50μm; scale bars for (B,D) = 20μm. Immunochemistry was performed
using the same materials and procedures described in detail by Zhou et al.
(2012a).
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examination of the kidney but, nevertheless, this was in contrast
to the severe phenotype of constitutive TonEBP/NFAT5 knockout
mice with embryonic/fetal deletion of TonEBP/NFAT5. The few
surviving knockout mice displayed renal atrophy, increased apop-
tosis and impaired activation of osmoprotective genes (Lopez-
Rodriguez et al., 2004).
TonEBP/NFAT5 is not exclusive for the BGT1 gene, it also
regulates several other osmolyte transporter genes including the
sodium/myo-inositol cotransporter 1 (SMIT1; slc5a3) (Miyakawa
et al., 1999a) and the taurine transporter (TAUT; slc6a6) (Zhang
et al., 2003), as well as aldose reductase which converts glucose to
sorbitol (Ferraris et al., 1996; Ko et al., 1997). Modulation of these
osmolyte cotransporters can be achieved by divergent regula-
tory pathways (Miyakawa et al., 1999a). The regional distribution
of TonEBP/NFAT5, aldose reductase, osmolyte transporters, and
osmolytes within the principal zones of the kidney has been
described by several different laboratories. These data have been
collected from the literature and are summarized in Figure 3.
Note the close correlation with the distribution of their respec-
tive targets. The widespread distribution of TonEBP throughout
the outer and inner medulla allows it to regulate expression of
aldose reductase and the osmolyte transporters even though their
distributions are different. The most notable differences are the
restriction of aldose reductase to the inner medulla and TAUT to
the outer stripe of the outer medulla. In contrast, SMIT1 has a
widespread distribution in all zones including, due to its loca-
tion in the macula densa, the cortex. Disruption of the aldose
reductase gene caused a defect in urinary concentrating ability
and divalent cation homeostasis (Aida et al., 2000). TAUT defi-
cient mice had renal taurine loss and their ability to lower urine
osmolality and increase urinary water excretion was impaired
(Huang et al., 2006). Mice lacking SMIT1 had more severe defects
but death was due to respiratory failure (Chau et al., 2005).
Further details of these knockout mice models are summarized in
Table 2. Perhaps deletion of two or more of them can reveal the
relative importance of these osmolytes in kidney function since
betaine, myo-inositol and sorbitol can substitute for each other
(Moriyama et al., 1991), consistent with their overlapping distri-
butions (Figure 3). Emerging evidence suggests the involvement
of TonEBP/NFAT5 in multiple cellular pathways in addition to
organic osmolyte-dependent pathways (Lee et al., 2011), and a
review on tonicity-independent regulation of TonEBP/NFAT5 has
been published recently (Halterman et al., 2012).
In summary, BGT1 plays an essential role in betaine accumu-
lation by renal medullary cells during adaptation to hypertonic
stress. However, the lack of BGT1 and betaine is not critical
for survival likely due to compensation by accumulation other
osmolytes.
BGT1 AND BETAINE IN LIVER
Like the kidneys, rat liver also contains high concentrations of
betaine (Table 1) (Slow et al., 2009). However, under normal con-
ditions the liver is only slightly hypertonic, approximately 330–
335mosmol/kg (Go et al., 2004), in contrast to kidney medulla
where hypertonicity can reach 1000–1200mosmol/kg (Woo et al.,
2000). A role for BGT1 and betaine in liver cell volume regu-
lation cannot be ruled out completely, as suggested by studies
on the expression of betaine-homocysteine S-methyltransferase
(BHMT1) mRNA. This enzyme removes a methyl group from
betaine and is the major betaine catabolizing enzyme in liver
(Figure 4). Expression of BHMT1 mRNA in isolated hepatocytes
was decreased by hypertonicity consistent with preservation of
betaine content for osmoregulation. The reverse occurred dur-
ing hypotonicity, consistent with removal of intracellular betaine
(Hoffmann et al., 2013). In experiments in vivo, chronic plasma
hyposmolarity in rats was accompanied by decreases in mRNA
for TonEBP, SMIT1, and BGT1 in liver (Zhang et al., 2003). Taken
together, these findings are a good illustration of the importance
of volume regulation for cell survival. The adaptive responses may
very well-turn out to be conserved in most cells. In fact, sim-
ilar adaptive responses have been described in a variety of cell
types when grown in vitro. Because hepatocytes do not experi-
ence osmotic stress under normal conditions in vivo, it is unlikely
that BGT1 and betaine play important roles in osmoprotection
on a daily basis. Thus, it is possible that BGT1 and betaine accu-
mulation may be activated by pathological increases in plasma
osmolarity (e.g., hypernatremia or hyperglycemia), but that they
play other roles in normal situations.
Another important role of betaine is one-carbon metabolism.
This is important for liver function and argues that the pri-
mary role of hepatic betaine is to act as a methyl donor. This
is in agreement with the finding that the expression of BHMT1
mRNA is at least 50-fold more abundant in mouse liver than
any other tissue (Zhou et al., 2012a). A disturbance of hep-
atic one-carbon metabolism can lead to liver diseases including
fatty liver, steatosis and hepatocellular carcinoma (Mato et al.,
2008). Betaine contributes significantly to the transmethylation
of homocysteine to methionine (Figure 4) because the BHMT1
pathway is a major route for the elimination of homocysteine
(cardiovascular risk factor) and catabolism of betaine (Teng et al.,
2012a). Deletion of the BHMT1 gene in mice resulted in fatty
liver and hepatocellular carcinomas (Teng et al., 2011). Hepatic
betaine is derived from two sources: an endogenous source which
is de novo synthesis from dietary choline (Figure 4), an essential
nutrient (Johnson et al., 2010; Zeisel, 2012), and an exogenous
source due to dietary betaine (Clow et al., 2008). Which route is
the major pathway? In rodent liver betaine is not unusually high
(approximately 1–2μmol/g, Table 1), but when betaine is sup-
plemented in the diet it can increase up to 5 fold (∼10μmol/g)
(Schwahn et al., 2004; Clow et al., 2008). Deletion of choline dehy-
drogenase (converts choline to betaine, Figure 4) in mice did not
affect liver function, in spite of alteration of choline metabolites
(Johnson et al., 2010). On the other hand, dietary betaine sup-
plements have been reported to reduce liver injury induced by
a variety of toxins such as carbon tetrachloride (Junnila et al.,
2000), alcohol (Barak et al., 2003; Kharbanda et al., 2012) and
lipopolysaccharide (Craig, 2004). Betaine supplements also have
been reported to improve liver function in non-alcoholic fatty
liver disease (Abdelmalek et al., 2001, 2009; Wang et al., 2010).
However, addition of the methyl donor betaine cannot prevent
apoptotic death induced by choline deficiency in hepatocytes
(Shin et al., 1997). This is probably because part of the choline
requirement must be supplied as choline per se, but the addition
of betaine from diet allows a marked reduction in the total dietary
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FIGURE 3 | Schematic illustration of the distributions of TonEBP, BGT1,
AR, SMIT1, and TAUT as well as the related osmolytes in the kidney.
TonEBP is present in most tubular profiles in the medulla, including the loop
of Henle and medullary collecting ducts and interstitial cells (Han et al.,
2004). BGT1 is present in the medullary thick ascending limbs of Henle loop
and the medullary collecting ducts (Miyai et al., 1996; Zhou et al., 2012a).
Aldose reductase (AR) is in the loop of Henle and inner medullary collecting
(Continued)
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FIGURE 3 | Continued
ducts (Terubayashi et al., 1989; Schwartz et al., 1992; Grunewald et al., 2001).
SMIT1 is predominantly present in the medullary and cortical thick ascending
limb of Henle’s loop and in the cells of the macula densa as well as to a
lesser extent in the inner medullary collecting ducts (Yamauchi et al., 1995).
TAUT is localized to the proximal tubules in the outer stripe of outer medulla
(Park et al., 1989; Lopez-Rodriguez et al., 2004). Organic osmolytes including
betaine and sorbitol exhibit their highest concentrations in the papillary tip,
except myo-inositol which has similar high concentrations in inner and outer
medulla (Wirthensohn et al., 1989; Yancey and Burg, 1989).
Table 2 | Summary of the phenotype of relevant knockout mice.
Gene name Expression pattern Phenotype References
TonEBP (NFAT5,
NFATL1, OREBP)
Thymus, placenta, brain, spinal cord,
heart, liver > salivary gland, lung,
kidney, gut, bladder
Show perinatal lethality; the majority of the few
survivors died around P10; display progressive
growth retardation; renal atrophy; exhibit abnormal
heart development; increased severity of neuronal
cell death in ischemic injury; lymphoid hypocellularity
and impaired antigen-specific antibody responses;
reduced cell proliferation
Trama et al., 2000; Maouyo
et al., 2002; Go et al., 2004;
Lopez-Rodriguez et al., 2004;
Mak et al., 2011, 2012
SMIT1 (SLC5A3) Kidney > brain Die shortly after birth probably because of abnormal
respiratory rhythmogenesis or severe defects in the
pheripheral nerve; no decrease in phophatidylinositol
in spite of severe myo-inositol deficiency; lethality can
be rescued by supplement of exogenous
myo-inositol; shows a lithium-like phenotype but has
no effect on lithium-sensitive behavior
Kwon et al., 1992; Berry
et al., 2003; Chau et al.,
2005; Shaldubina et al., 2006;
Bersudsky et al., 2008
Aldose reductase
(hAKR1B1, mAkr1b3,
EC1.1.1.21)
Testis, heart, retina, len, sciatic nerve,
kidney, skeletal muscle, small
intestines, thymus, spleen, placenta
> brain, lung, pancreas > liver
Viable; fertile; develop polyuria and polydipsia; exhibit
a partial defective urine-concentrating ability and a
defect in divalent cation homeostasis; leads to
nephrogenic diabetes insipidus; ameliorated
diabetes-induced renal hypertrophy and nerve
degeneration; improves cerebral or retinal ischemic
injuries
Nishimura et al., 1988; Cao
et al., 1998; Aida et al., 2000;
Ho et al., 2000, 2006; Yang
et al., 2006; Lo et al., 2007;
Zhou et al., 2014
BGT1 (mGAT2,
SLC6A12)
Liver > kidney, brain Viable; fertile; appear to tolerate salt drinking
(concentrate urine normally); no decreased
susceptibility in electrical and chemical induced
seizure
Lehre et al., 2011; Zhou et al.,
2012a
TAUT (SLC6A6) Kidney, brain, retina, small intestine,
spleen, heart, skeletal muscle > liver,
epididymis, pancreas (islet)
Viable; reduced fertility; reduced weight; decreased
taurine levels in a variety of tissues; impaired ability
to increase water excretion and to lower urine
osmolarity; vision loss due to severe retinal
degeneration; show electromyographic abnormalities
and reduced total exercise capacity; leads to
cardiomyopathy with cardiac atrophy; higher
sensitivity to ultraviolet B radiation-induced
immunosuppression; loss of ability to self-heal
malaria; develop chronic liver disease in old age;
reduced ability to develop long-lasting enhancement
of synaptic transmission in the striatum; reduced
apoptosis of erythrocytes during exposure to osmotic
shock or oxidative stress
Liu et al., 1992; Smith et al.,
1992; Uchida et al., 1992; Ito
et al., 2008; Delic et al., 2010;
Zhou et al., 2014
choline requirement (Dilger et al., 2007). To investigate the rela-
tive importance of these two sources of betaine (Shin et al., 1997;
Dilger et al., 2007; Teng et al., 2012b) identification of the betaine
transport mechanisms in hepatocytes will be needed, and a good
animal model will be essential.
The accumulation of betaine has been suggested to be primar-
ily by BGT1 and amino acid transport system A (Craig, 2004;
Burg and Ferraris, 2008) but other transporters also may be
involved, see below. The contribution of BGT1 to the total capac-
ity of hepatocytes to accumulate betaine has not been determined.
Compared to the extensive investigations on renal BGT1, the role
of liver BGT1 has received little attention. This in part is because
it was thought to be absent from rat hepatocytes, and only present
in less abundant Kupffer and endothelial cells (Zhang et al., 1996;
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FIGURE 4 | Role of betaine in the methionine cycle in liver. Betaine
provides an alternative pathway for methylation of homocysteine. BHMT,
betaine-homocysteine S-methyltransferase. MS, methionine synthase.
Modified from Craig (2004).
Weik et al., 1998). Recently we showed that it is the other way
around. BGT1 is primarily expressed in hepatocytes while expres-
sion in other liver cell types needs to be tested. BGT1 is present
in hepatocyte plasma membranes facing blood vessels (Figure 5)
(Zhou et al., 2012a). In the mouse the abundance of BGT1 in
liver far exceeds that in the kidney (Zhou et al., 2012a). In con-
trast to renal medullary cells where BGT1 remains intracellular
until the onset of hypertonic stress, BGT1 in hepatocytes is always
localized to the plasma membrane even during isotonic condi-
tions (Kempson et al., 2013). This unexpected plasma membrane
location in mouse hepatocytes grown in culture under isotonic
conditions is probably due to the reported transcriptional activ-
ity of TonEBP/NAFT5 at normal osmolarity (Ho, 2003; Zhang
et al., 2003; Cheung and Ko, 2013) and the differential expres-
sion of BGT1 mRNA isoforms in liver (Takenaka et al., 1995).
However, it has not been determined if liver BGT1 is regulated by
TonEBP. Thus, liver BGT1 is ideally localized for import of betaine
into hepatocytes from the circulation which would maintain the
supply of betaine for hepatocyte metabolism. It also has been
reported (Wettstein et al., 1998) that hepatocyte uptake of betaine
was not stimulated by hyperosmolarity, and it was suggested
that hepatocytes may release some of the accumulated betaine
for use as an osmolyte by nearby Kupffer cells and endothelial
cells. Kupffer cells, the resident liver macrophages, adhere to the
endothelial cells of the liver sinusoids and account for the central
role of the liver in systemic and regional defense. They are the first
macrophage population in the body to encounter bacteria and
endotoxins that are delivered to the liver from the gastrointesti-
nal tract via the portal vein (Bilzer et al., 2006). In this location
the capacity for osmoadaptation may be critical for the survival
and normal function of Kupffer cells.
BGT1 transport activity in hepatocytes in primary cell cul-
ture was characterized using betaine as the substrate rather than
GABA because of the report of a GABA carrier (GAT2) in hepato-
cytes (Ikeda et al., 2012). In our initial experiments the uptake
of [14C]betaine by isolated hepatocytes was sodium dependent
FIGURE 5 | BGT1 localization in the liver. The section was double labeled
with anti-CD31 antibodies (green; 0.5μg/ml; endothelial marker) and
anti-BGT1 antibodies (red; Ab#594; 1μg/ml). Scale bars = 20μm.
Immunochemistry was performed using the same materials and
procedures described in detail by Zhou et al. (2012a).
and was partly inhibited by quinidine and nipecotic acid, simi-
lar to the activity of the renal BGT1 transporter (Yamauchi et al.,
1992; Kempson et al., 2003). We also noted that [14C]betaine
transport was partly inhibited by α-methylaminoisobutryic acid
and carnitine (Kempson et al., 2013). This implies that multi-
ple pathways might be involved in accumulating betaine, such as
the system A amino acid transporter family (SNAT 1, 2 and 4)
(Hatanaka et al., 2001; Bode et al., 2002) and the ubiquitous car-
nitine transporter (OCTN2) (Yokogawa et al., 1999). If true, this
would help explain why BGT1 knockout mice are not severely
impaired (Lehre et al., 2011). Determining the contribution by
BGT1 to the total betaine uptake will require identification of
the betaine transport mechanisms in hepatocytes from the BGT1
knockout mice.
CONCLUSIONS
Betaine is found in many plants, animals, microorganisms and
in mammals. In addition to its role as an osmolyte, its metabolic
role has been shown to be important in protection of the liver
and other tissues and in alleviating cardiovascular risk factors
such as homocysteine. Consequently it has been suggested that
betaine is an important nutrient for prevention of chronic dis-
ease (Craig, 2004). A summary of the multiple roles of betaine
and BGT1 in the tissues discussed in this review is presented in
Table 3. Both are present in brain but their roles are least under-
stood in this tissue. Betaine is of undoubted importance for liver
metabolism, but the importance of BGT1 for betaine transport
remains unclear even though its abundance in liver is almost
50-fold greater compared to the kidney. The best documented
roles are in the kidney where betaine serves as one of several
compatible osmolytes that are accumulated by cells in the renal
medulla in order to adapt to the high extracellular osmolarity.
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Table 3 | Summary of functions of BGT1 and betaine in mouse tissues.
Tissue Primary
substrate
for BGT1
BGT1
abundance
in tissue
BGT1 location Principal role of BGT1 BGT1
regulated
by TonEBP
Betaine
content
of tissue
Principal role of
betaine
Brain Unknown
(Betaine or
GABA)
Low Leptomeninges Unknown. Low affinity
for GABA compared to
GAT transporters
Unknown Low Not an important
osmolyte. Possible
role as extracellular
signaling ligand
Kidney Betaine High Basolateral in medullary cells
(thick ascending limbs of Henle
and collecting ducts). Highest
levels at the tip of the renal papilla
Betaine transport for cell
volume regulation during
hypertonic stress
Yes High Compatible osmolyte
in medullary cells
Liver Betaine Highest Hepatocyte plasma membranes Primary role in betaine
transport for one-carbon
metabolism. Possible
secondary role in volume
regulation
Unknown High Primary role as
methyl group donor
in liver metabolism
(methionine cycle).
Possible secondary
role as osmolyte
See text for further details.
This is facilitated by upregulation of BGT1 expression mediated
by the transcription factor TonEBP/NFAT5. Due to the significant
difficulties in replicating in vitro the normal cellular microen-
vironments present in vivo, complete evaluation of the roles of
BGT1 and betaine (and other osmolyte transporters) in these tis-
sues in vivo will require further genetic manipulation in whole
animals.
The knockout mouse models currently available (Table 2) also
serve as excellent negative controls for verifying antibody speci-
ficity which is essential for accurate interpretation of immuno-
histochemical data (Danbolt et al., 1998; Holmseth et al., 2005,
2012). The story about EF1502 and inhibition of brain BGT1
illustrates how much the biomedical research community relies
on accurate localization data to interpret data obtained with
other methods such as pharmacology experiments (Lehre and
Rusakov, 2002; Rusakov et al., 2005; Holmseth et al., 2012). When
designing new CNS active drugs virtually all receptors, metabolic
enzymes and transporters should be considered as valid targets
(Kowalczyk et al., 2012; Salat et al., 2012). So although EF1502
was tested on a fair number of targets, it is not possible to test all.
Further, it is important to keep in mind that cultured astrocytes
may differ substantially from mature brain astrocytes (Cahoy
et al., 2008).
The ability to use osmolytes to adapt to osmotic stress has
been conserved in all cells because it is vital for survival and
TonEBP/NFAT5 is expressed at basal levels in all tissues in the
body (Halterman et al., 2012). However, the many observations of
osmolyte accumulation by cultured cells during hypertonic stress
in vitro should not lead to the conclusion that the same cells are
exposed to hypertonic stress in vivo. In fact, only a limited number
of tissues experience hyperosmotic stress under normal condi-
tions. It has been suggested that the activation of TonEBP/NFAT5
by hypertonicity in the kidney medulla may be a specialized adap-
tation of its normal role under iso-osmotic conditions (Trama
et al., 2002), namely its regulation by tonicity-independent factors
critical for cell survival, mitogenesis and migration (Halterman
et al., 2012). The presence of TonEBP/NFAT5 in all cells allows
the possibility of regulation by cell-specific factors and permits a
role in activating cell-specific gene transcription (Cheung and Ko,
2013).
Finally it should be noted that the responses to hyperosmotic
stress have been thoroughly investigated and identified in the
kidney due to its unique structure and function. More recently,
studies have revealed that non-renal tissues commonly experi-
ence hyperosmotic stress, especially under pathological condi-
tions such as hypernatremia and hyperglycemia (Brocker et al.,
2012). For example, in response to the chronic hyperglycemia
found in diabetics, glucose flux through the polyol pathway is
increased and accounts for about one third of total glucose con-
sumption. In this pathway aldose reductase converts glucose to
sorbitol and the resultant accumulation of intracellular sorbitol
causes hyperosmotic stress (Cheng and Gonzalez, 1986). Aldose
reductase occurs not only in the renal medulla but also in other
organs and has long been believed to be responsible for sec-
ondary diabetic complications such as retinopathy, neuropathy,
nephropathy, and caractogenesis.
Taking a broader view, a number of studies have reported a
strong association between localized hypertonicity and inflam-
mation (Hubert et al., 2004; Schwartz et al., 2009). The contri-
bution of osmotic stress to the development and progression of
chronic inflammatory diseases, such as arthritis and inflamma-
tory bowel disease (IBD), is not well-understood. However, in the
case of IBD, recent research suggests that episodes of local hyper-
osmotic stress can upregulate the release of pro-inflammatory
cytokines by colorectal epithelial cells (Abolhassani et al., 2008;
Schwartz et al., 2008). Future studies may reveal that therapeu-
tics targeting localized hyperosmotic adaptation could represent
a novel class of drugs for the treatment of many disorders.
For example, inhibitors of aldose reductase have been shown to
prevent inflammatory complications such as sepsis and asthma
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(Srivastava et al., 2005; Ramana, 2011). Perhaps localized inhibi-
tion of other features of hyperosmotic adaptation, such as BGT1
and other osmolyte transporters, also may be useful in preventing
inflammation.
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